Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Akihito Kawazoe; Noboru Yamamoto; Naotoshi Sugimoto; Hisato Kawakami; Takashi Oshima; Kensei Yamaguchi; Kaori Hino; Motohiro Hirao; Yukinori Kurokawa; Takeshi Kawakami; Masahiro Tsuda; Hiroki Hara; Shota Kaname; Daiko Matsuoka; Yohei Otake; Keisuke Yasuda; Takao Takase; Shuya Takashima; Taro Semba; Kei Muro

doi:10.1158/1078-0432.25515822

Abstract

Supplementary Fig S2. Absolute neutrophil counts in patients who received prophylactic pegGCSF (A) and in patients who did not receive prophylactic peg-GCSF (B), by visit

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Kawazoe et al. (2024) studied this question.

synapsesocial.com/papers/68e712deb6db64358768c0e6 https://doi.org/10.1158/1078-0432.25515822

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers